Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
- PMID: 16132115
- PMCID: PMC7089214
- DOI: 10.1007/s11373-005-9004-3
Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
Abstract
The spike (S) glycoprotein is thought to play a complex and central role in the biology and pathogenesis of SARS coronavirus infection. In this study, a recombinant protein (rS268, corresponding to residues 268-1255 of SARS-CoV S protein) was expressed in Escherichia coli and was purified to near homogeneity. After immunization with rS268, S protein-specific BALB/c antisera and mAbs were induced and confirmed using ELISA, Western blot and IFA. Several BALB/c mAbs were found to be effectively to neutralize the infection of Vero E6 cells by SARS-CoV in a dose-dependent manner. Systematic epitope mapping showed that all these neutralizing mAbs recognized a 15-residues peptide (CB-119) corresponding to residues 1143-1157 (SPDVDLGDISGINAS) that was located to the second heptad repeat (HR2) region of the SARS-CoV spike protein. The peptide CB-119 could specifically inhibit the interaction of neutralizing mAbs and spike protein in a dose-dependent manner. Further, neutralizing mAbs, but not control mAbs, could specifically interact with CB-119 in a dose-dependent manner. Results implicated that the second heptad repeat region of spike protein could be a good target for vaccine development against SARS-CoV.
Similar articles
-
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.J Immunol. 2005 Apr 15;174(8):4908-15. doi: 10.4049/jimmunol.174.8.4908. J Immunol. 2005. PMID: 15814718
-
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.Vaccine. 2006 Jun 29;24(26):5498-508. doi: 10.1016/j.vaccine.2006.04.054. Epub 2006 May 11. Vaccine. 2006. PMID: 16725238 Free PMC article.
-
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.J Virol. 2005 Feb;79(3):1635-44. doi: 10.1128/JVI.79.3.1635-1644.2005. J Virol. 2005. PMID: 15650189 Free PMC article.
-
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.Rev Med Virol. 2012 Jan;22(1):2-17. doi: 10.1002/rmv.706. Epub 2011 Sep 8. Rev Med Virol. 2012. PMID: 21905149 Free PMC article. Review.
-
SARS vaccine development.Emerg Infect Dis. 2005 Jul;11(7):1016-20. doi: 10.3201/1107.050219. Emerg Infect Dis. 2005. PMID: 16022774 Free PMC article. Review.
Cited by
-
De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model.Nat Commun. 2024 Aug 10;15(1):6867. doi: 10.1038/s41467-024-50903-y. Nat Commun. 2024. PMID: 39127753 Free PMC article.
-
SARS-CoV-2 spike S2-specific neutralizing antibodies.Emerg Microbes Infect. 2023 Dec;12(2):2220582. doi: 10.1080/22221751.2023.2220582. Emerg Microbes Infect. 2023. PMID: 37254830 Free PMC article. Review.
-
Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions.Heliyon. 2023 Jan;9(1):e12890. doi: 10.1016/j.heliyon.2023.e12890. Epub 2023 Jan 13. Heliyon. 2023. PMID: 36686609 Free PMC article.
-
Humoral Immune Response Profile of COVID-19 Reveals Severity and Variant-Specific Epitopes: Lessons from SARS-CoV-2 Peptide Microarray.Viruses. 2023 Jan 15;15(1):248. doi: 10.3390/v15010248. Viruses. 2023. PMID: 36680289 Free PMC article.
-
A dataset comprised of binding interactions for 104,972 antibodies against a SARS-CoV-2 peptide.Sci Data. 2022 Oct 26;9(1):653. doi: 10.1038/s41597-022-01779-4. Sci Data. 2022. PMID: 36289234 Free PMC article.
References
-
- Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New Engl. J. Med. 2003;348:1967–1976. doi: 10.1056/NEJMoa030747. - DOI - PubMed
-
- Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. New Engl. J. Med. 2003;348:1953–66. - PubMed
-
- Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325. doi: 10.1016/S0140-6736(03)13077-2. - DOI - PMC - PubMed
-
- Lai, M.M.C., Holmes K.V., et al. In: Knipe D.M. and Howley P.M. (Eds), Coronaviridae: The Viruses and their Replication. Lippincott Williams and Wilkins, London, 2001, 1163–1185.
-
- Fazakerley J.K., Parker S.E., Bloom F., Buchmeier M.J. The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. Virology. 1992;187:178–188. doi: 10.1016/0042-6822(92)90306-A. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous